Nasdaq · Healthcare
IRONWOOD PHARMACEUTICALS INC (IRWD)
As-reported financials and recent SEC filings for IRONWOOD PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$296.2M
Net income
$24.0M
Net margin
8.1%
Diluted EPS
$0.15
ROE
-9.2%
P/E (TTM)
6.7×
Market cap
$679.9M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M |
| Gross profit | — | — | — | — | — |
| Operating income | $98.5M | $93.1M | $-945.4M | $250.3M | $232.3M |
| Net income | $24.0M | $880,000 | $-1.00B | $175.1M | $528.4M |
| Diluted EPS | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-18
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →Go deeper on IRWD
Search IRONWOOD PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.